313 related articles for article (PubMed ID: 26558621)
1. Non-Adrenergic Vasopressors in Patients with or at Risk for Vasodilatory Shock. A Systematic Review and Meta-Analysis of Randomized Trials.
Belletti A; Musu M; Silvetti S; Saleh O; Pasin L; Monaco F; Hajjar LA; Fominskiy E; Finco G; Zangrillo A; Landoni G
PLoS One; 2015; 10(11):e0142605. PubMed ID: 26558621
[TBL] [Abstract][Full Text] [Related]
2. Vasopressin and terlipressin in adult vasodilatory shock: a systematic review and meta-analysis of nine randomized controlled trials.
Serpa Neto A; Nassar AP; Cardoso SO; Manetta JA; Pereira VG; Espósito DC; Damasceno MC; Russell JA
Crit Care; 2012 Aug; 16(4):R154. PubMed ID: 22889256
[TBL] [Abstract][Full Text] [Related]
3. Vasopressor therapy in critically ill patients with shock.
Russell JA
Intensive Care Med; 2019 Nov; 45(11):1503-1517. PubMed ID: 31646370
[TBL] [Abstract][Full Text] [Related]
4. Association of Vasopressin Plus Catecholamine Vasopressors vs Catecholamines Alone With Atrial Fibrillation in Patients With Distributive Shock: A Systematic Review and Meta-analysis.
McIntyre WF; Um KJ; Alhazzani W; Lengyel AP; Hajjar L; Gordon AC; Lamontagne F; Healey JS; Whitlock RP; Belley-Côté EP
JAMA; 2018 May; 319(18):1889-1900. PubMed ID: 29801010
[TBL] [Abstract][Full Text] [Related]
5. Novel Vasopressors in the Treatment of Vasodilatory Shock: A Systematic Review of Angiotensin II, Selepressin, and Terlipressin.
Rodriguez R; Cucci M; Kane S; Fernandez E; Benken S
J Intensive Care Med; 2020 Apr; 35(4):327-337. PubMed ID: 30563433
[TBL] [Abstract][Full Text] [Related]
6. The Effect of inotropes and vasopressors on mortality: a meta-analysis of randomized clinical trials.
Belletti A; Castro ML; Silvetti S; Greco T; Biondi-Zoccai G; Pasin L; Zangrillo A; Landoni G
Br J Anaesth; 2015 Nov; 115(5):656-75. PubMed ID: 26475799
[TBL] [Abstract][Full Text] [Related]
7. Role of vasopressin and terlipressin in refractory shock compared to conventional therapy in the neonatal and pediatric population: a systematic review, meta-analysis, and trial sequential analysis.
Masarwa R; Paret G; Perlman A; Reif S; Raccah BH; Matok I
Crit Care; 2017 Jan; 21(1):1. PubMed ID: 28057037
[TBL] [Abstract][Full Text] [Related]
8. Pharmacologic Agents for the Treatment of Vasodilatory Shock.
Knotzer H; Poidinger B; Kleinsasser A
Curr Pharm Des; 2019; 25(19):2133-2139. PubMed ID: 31272348
[TBL] [Abstract][Full Text] [Related]
9. Vasopressor-Sparing Action of Methylene Blue in Severe Sepsis and Shock: A Narrative Review.
Puntillo F; Giglio M; Pasqualucci A; Brienza N; Paladini A; Varrassi G
Adv Ther; 2020 Sep; 37(9):3692-3706. PubMed ID: 32705530
[TBL] [Abstract][Full Text] [Related]
10. Role of vasopressin in the management of septic shock.
Mutlu GM; Factor P
Intensive Care Med; 2004 Jul; 30(7):1276-91. PubMed ID: 15103461
[TBL] [Abstract][Full Text] [Related]
11. Vasopressors for the Treatment of Septic Shock: Systematic Review and Meta-Analysis.
Avni T; Lador A; Lev S; Leibovici L; Paul M; Grossman A
PLoS One; 2015; 10(8):e0129305. PubMed ID: 26237037
[TBL] [Abstract][Full Text] [Related]
12. Vasopressors for hypotensive shock.
Gamper G; Havel C; Arrich J; Losert H; Pace NL; Müllner M; Herkner H
Cochrane Database Syst Rev; 2016 Feb; 2(2):CD003709. PubMed ID: 26878401
[TBL] [Abstract][Full Text] [Related]
13. Vasopressin and methylene blue: alternate therapies in vasodilatory shock.
Lavigne D
Semin Cardiothorac Vasc Anesth; 2010 Sep; 14(3):186-9. PubMed ID: 20705641
[TBL] [Abstract][Full Text] [Related]
14. Vasopressors for hypotensive shock.
Havel C; Arrich J; Losert H; Gamper G; Müllner M; Herkner H
Cochrane Database Syst Rev; 2011 May; (5):CD003709. PubMed ID: 21563137
[TBL] [Abstract][Full Text] [Related]
15. The pharmacotherapeutic options in patients with catecholamine-resistant vasodilatory shock.
Albertson TE; Chenoweth JA; Lewis JC; Pugashetti JV; Sandrock CE; Morrissey BM
Expert Rev Clin Pharmacol; 2022 Aug; 15(8):959-976. PubMed ID: 35920615
[TBL] [Abstract][Full Text] [Related]
16. Vasopressin and terlipressin in neonates and children with refractory septic shock.
Biban P; Gaffuri M
Curr Drug Metab; 2013 Feb; 14(2):186-92. PubMed ID: 23439212
[TBL] [Abstract][Full Text] [Related]
17. [Methylene blue in the treatment of vasodilatory shock: a Meta-analysis].
Zhang X; Gao Y; Pan P; Wang Y; Li W; Yu X
Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2017 Nov; 29(11):982-987. PubMed ID: 29151412
[TBL] [Abstract][Full Text] [Related]
18. [Vasopressin and terlipressin in sepsis and systemic inflammatory response syndrome. Effects on microcirculation, oxygen transport, metabolism and organ function].
Ertmer C; Sielenkämper AW; van Aken H; Bone HG; Westphal M
Anaesthesist; 2005 Apr; 54(4):346-56. PubMed ID: 15625598
[TBL] [Abstract][Full Text] [Related]
19. Vasopressin for treatment of vasodilatory shock: an ESICM systematic review and meta-analysis.
Polito A; Parisini E; Ricci Z; Picardo S; Annane D
Intensive Care Med; 2012 Jan; 38(1):9-19. PubMed ID: 22127480
[TBL] [Abstract][Full Text] [Related]
20. [Vasopressin and its analogues in the therapy of shock].
Novák F; Lubanda H; Onderková R; Zák A
Cas Lek Cesk; 2004; 143(5):307-8, 310-2. PubMed ID: 15305765
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
